Literature DB >> 9573285

Immunoglobulin G, plasma cells, and lymphocytes in the murine vagina after vaginal or parenteral immunization with attenuated herpes simplex virus type 2.

E L Parr1, M B Parr.   

Abstract

This investigation evaluated immunity to vaginal herpes simplex virus type 2 (HSV-2) infection after local or parenteral immunization with attenuated HSV-2. Vaginal immunization induced sterilizing immunity against challenge with a high dose of wild-type virus, whereas parenteral immunizations protected against neurologic disease but did not entirely prevent infection of the vagina. Vaginal immunization caused 86- and 31-fold increases in the numbers of immunoglobulin G (IgG) plasma cells in the vagina at 6 weeks and 10 months after immunization, whereas parenteral immunizations did not increase plasma cell numbers in the vagina. Vaginal secretion/serum titer ratios and specific antibody activities in vaginal secretions and serum indicated that IgG viral antibody was produced in the vagina and released into vaginal secretions at 6 weeks and 10 months after vaginal immunization but not after parenteral immunizations. In contrast to the case for plasma cells, the numbers of T and B lymphocytes in the vagina were similar in vaginally and parenterally immunized mice. Also, lymphocyte numbers in the vagina were markedly but similarly increased by vaginal challenge with HSV-2 in both vaginally and parenterally immunized mice. Lymphocyte recruitment to the vagina after virus challenge appeared to involve memory lymphocytes, because it was not observed in nonimmunized mice. Thus, local vaginal immunization with attenuated HSV-2 increased the number of IgG plasma cells in the vagina and increased vaginal secretion/serum titer ratios to 3.0- to 4.7-fold higher than in parenterally immunized groups but caused little if any selective homing of T and B lymphocytes to the vagina.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9573285      PMCID: PMC110083          DOI: 10.1128/JVI.72.6.5137-5145.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Immune and inflammatory responses to reproductive tract infection with Tritrichomonas foetus in immunized and control heifers.

Authors:  M L Anderson; R H BonDurant; R R Corbeil; L B Corbeil
Journal:  J Parasitol       Date:  1996-08       Impact factor: 1.276

2.  Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2.

Authors:  E L Parr; M B Parr
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Distribution of antigen specific memory T cells in lymph nodes after immunization at peripheral or mucosal sites.

Authors:  R R Premier; H J Jacobs; M R Brandon; E N Meeusen
Journal:  Immunol Cell Biol       Date:  1996-06       Impact factor: 5.126

4.  Induction of Th2 cytokine expression for p27-specific IgA B cell responses after targeted lymph node immunization with simian immunodeficiency virus antigens in rhesus macaques.

Authors:  S Kawabata; C J Miller; T Lehner; K Fujihashi; M Kubota; J R McGhee; K Imaoka; T Hiroi; H Kiyono
Journal:  J Infect Dis       Date:  1998-01       Impact factor: 5.226

Review 5.  Interleukin-8 and related chemotactic cytokines--CXC and CC chemokines.

Authors:  M Baggiolini; B Dewald; B Moser
Journal:  Adv Immunol       Date:  1994       Impact factor: 3.543

6.  Mucosal and systemic antiviral antibodies in mice inoculated intravaginally with herpes simplex virus type 2.

Authors:  M R McDermott; L J Brais; M J Evelegh
Journal:  J Gen Virol       Date:  1990-07       Impact factor: 3.891

7.  Expression of immunity to intravaginal herpes simplex virus type 2 infection in the genital tract and associated lymph nodes.

Authors:  M R McDermott; P L Brais; G C PLoettsche; M J Evelegh; C H Goldsmith
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

8.  Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity.

Authors:  P L Fidel; M E Lynch; D H Conaway; L Tait; J D Sobel
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

9.  Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection.

Authors:  A Cassone; M Boccanera; D Adriani; G Santoni; F De Bernardis
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

10.  Infection by bovine papillomavirus and prospects for vaccination.

Authors:  M S Campo
Journal:  Trends Microbiol       Date:  1995-03       Impact factor: 17.079

View more
  21 in total

1.  Immune responses and protection against vaginal infection after nasal or vaginal immunization with attenuated herpes simplex virus type-2.

Authors:  E L Parr; M B Parr
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

2.  Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles.

Authors:  Soumi Gupta; Ramesh Janani; Qian Bin; Paul Luciw; Catherine Greer; Silvia Perri; Harold Legg; John Donnelly; Susan Barnett; Derek O'Hagan; John M Polo; Michael Vajdy
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 3.  Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes.

Authors:  Mingke Yu; Michael Vajdy
Journal:  Expert Opin Biol Ther       Date:  2010-08       Impact factor: 4.388

Review 4.  HSV-2: in pursuit of a vaccine.

Authors:  Christine Johnston; David M Koelle; Anna Wald
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

5.  Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease.

Authors:  Staffan Görander; Ali M Harandi; Madelene Lindqvist; Tomas Bergström; Jan-Åke Liljeqvist
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

6.  Immunity to vaginal HSV-2 infection in immunoglobulin A knockout mice.

Authors:  M B Parr; G R Harriman; E L Parr
Journal:  Immunology       Date:  1998-10       Impact factor: 7.397

7.  Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity.

Authors:  Lbachir BenMohamed; Georges Bertrand; Cory D McNamara; Helene Gras-Masse; Juergen Hammer; Steven L Wechsler; Anthony B Nesburn
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

8.  Herpes simplex virus (HSV)-specific T cells activated in the absence of IFN-gamma express alternative effector functions but are not protective against genital HSV-2 infection.

Authors:  Alison J Johnson; Michelle H Nelson; Melanie D Bird; Chin-Fun Chu; Gregg N Milligan
Journal:  J Reprod Immunol       Date:  2009-11-25       Impact factor: 4.054

9.  Mucosal innate and adaptive immune responses against herpes simplex virus type 2 in a humanized mouse model.

Authors:  Amanda Kwant-Mitchell; Ali A Ashkar; Kenneth L Rosenthal
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

10.  Replication-defective virus vaccine-induced protection of mice from genital herpes simplex virus 2 requires CD4 T cells.

Authors:  Lynda A Morrison
Journal:  Virology       Date:  2008-04-14       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.